Ref12p19
Japan.
J. Pharmacol. 60, 315-321 (1992)
Protective
Activity of Silipide (Siliphos®) on Liver Damage in Rodents
Marisa
Conti, Salvatore Malandrino and Maria Jose Magistretti
Inverni
della Beffa Research and Development Laboratiories, via Ripamonti
99, Milan Italy
See
National Library of Medicine Citation
The
aim of this study was to assess the effect of the silipide
(Siliphos®) against liver damage induced by different
agents.
The
results of this study showed a significant and dose related
protective activity against liver damage induced by toxic
agents with different mechanisms of action. One of the poisons
tested against was galactosomine which mimics hepatitis in
its effect on the liver.
The constituents of silipide (Siliphos®), on their own,
were devoid of any significant activity at doses equivalent
to those contained in the active doses of silipide (Siliphos®).
The
oral efficacy of silipide (Siliphos®) and the lack of
activity of the uncomplexed silybin indicate that silybin
reaches active concentrations at the site of action only when
administered as a complex. (1, 2)
Favorable
results of preliminary clinical trials (3,4) indicate that
silipide (Siliphos®) can be considered as a promising
new therapeutic agent for the treatment of hepatic disorders.
Morazzoni,
P, Magistretti, M.J., Giachetti, C. and Zanolo, G.: Comparative
bioavailability of IdB 1016 (Siliphos®), a new flavanolignan
complex , in rats. Eur. J. Drug Metab. Parmacokinet. 17, 39-44
(1992)
Barzaghi,
N., Crema, F., Gatti, G., Pifferi, G. and Perucca, E.: Pharmacokinetic
studies on IdB 1016, a silybiin-phosphatidylcholine complex,
in healthy human subjects. Eur. J. Drug Metab. Pharmacokinet.
15, 333-338 (1990)
Marena,
C. And Lampertico, M.: Preliminary clinical development of
silipide (Siliphos®): a new complex of silybin in toxic
liver disorders. Planta Med. 57, A124-A125 (1991)
Buzzelli,
G., Mascarella, S., Giusti, A., Marra, F., Pifferi, G., Marena,
C. and Gentilini, P.: Free radical scavenging effects of silybin-phosphatidylcholine
(Siliphos®) in pationes with chronic liver disease, preliminary
results. Abstracts of 26th meeting "European Association
for the Study of the Liver", September 1991, Palma de
Mallorca (Spain), S103 (1991)
|